INGENOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ingenol, and what generic alternatives are available?
Ingenol is a drug marketed by Padagis Israel and is included in two NDAs.
The generic ingredient in INGENOL is ingenol mebutate. There are three drug master file entries for this compound. Additional details are available on the ingenol mebutate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INGENOL?
- What are the global sales for INGENOL?
- What is Average Wholesale Price for INGENOL?
Summary for INGENOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| DailyMed Link: | INGENOL at DailyMed |
US Patents and Regulatory Information for INGENOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Israel | INGENOL MEBUTATE | ingenol mebutate | GEL;TOPICAL | 209018-001 | Jan 7, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Padagis Israel | INGENOL MEBUTATE | ingenol mebutate | GEL;TOPICAL | 209019-001 | Jan 9, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

